The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

The Food and Drug Administration on Thursday approved a new type of nonopioid painkiller from Vertex Pharmaceuticals, NBC ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Share prices of Moderna (NASDAQ: MRNA ... Within respiratory vaccines, the company anticipates FDA approval for an expanded indication of its RSV vaccine. Furthermore, the company has submitted ...